BioCentury on BioBusiness,
More money incoming
Monday, August 2, 1999
By Mike Ward& Eric Pierce
Europe's biotech entrepreneurs have yet another source of seed financing. Alan Goodman, one of Britain's leading biotech entrepreneurs, has announced a first closing of £12 million ($19 million) for Avlar BioVentures (Cambridge, U.K.), a seed and early-stage fund for U.K. and continental European opportunities. Investors in this round include 3i Group plc, BTG plc, the University of Cambridge, and Advanced Technology Management. The fund also received support through the European Union's Growth and Employment Initiative. Ultimately, Avlar seeks to create a pool of £20 million.
Avlar, formerly Quantum Healthcare Fund, plans to invest in companies focusing on therapeutics for unmet medical needs in cancer, inflammatory, and bone and metabolic disorders; drug delivery systems, medical diagnostic and imaging devices; and technology platforms in fields such as combinatorial chemistry, functional genomics, proteomics and gene therapy.
Goodman, who was the founder or co-founder of Peptide Therapeutics, Oxford BioMedica, Core Group, and CeNeS, plans for Avlar to take an active role in the early management of its companies, providing commercial, strategic and financial skills.
Avlar expects that its links with 3i's European network will help generate continental deal flow. 3i already has referred potential deals from Italy and Germany to the fund.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]